In an exclusive interview with ET Now, V Murlidharan, the CEO of Aurobindo Pharma’s Europe business, shared insights into the company’s success. According to Murlidharan, the key factors contributing to the company’s growth are the expansion of its product range and the steady increase in portfolio breadth. This has been achieved through a combination of in-house filings and in-licensing agreements.
Murlidharan highlighted the importance of the company’s launches, including day-one loss-of-exclusivity launches, which have enabled Aurobindo Pharma to capitalize on market opportunities. The ability to quickly respond to changes in the market and seize new opportunities has been a significant contributor to the company’s success.
The expansion of Aurobindo Pharma’s product portfolio has been a strategic focus for the company. By increasing the breadth of its offerings, the company has been able to diversify its revenue streams and reduce its dependence on a limited number of products. This has helped to mitigate risks and ensure a more stable financial performance.
In-licensing agreements have also played a crucial role in Aurobindo Pharma’s growth strategy. By partnering with other companies to acquire new products and technologies, the company has been able to accelerate its expansion into new markets and therapeutic areas. This approach has enabled Aurobindo Pharma to leverage the expertise and resources of its partners, while also reducing the risks and costs associated with developing new products.
Murlidharan’s comments suggest that Aurobindo Pharma’s success is the result of a combination of strategic planning, operational execution, and a willingness to adapt to changing market conditions. The company’s ability to capitalize on market opportunities, including day-one loss-of-exclusivity launches, has been a key factor in its growth. As the company continues to expand its product portfolio and explore new markets, it is well-positioned for future success. Overall, Aurobindo Pharma’s strategy of diversification, in-licensing, and strategic launches has enabled the company to achieve significant growth and establish itself as a major player in the European pharmaceutical market.